
Nearly 60 years after the first description by Barlow, mitral valve prolapse (MVP) still remains a diagnosis of great interest and intense controversy. This continuing concern is driven by the high prevalence of this valvular disorder, detected in 1.2%–2.4% of the general population, and its not infrequent association with symptoms including atypical chest pain, exertional dyspnoea, palpitations and anxiety
Like
Save
Share